192 related articles for article (PubMed ID: 9736919)
1. Matrix metalloproteinases.
Johnson LL; Dyer R; Hupe DJ
Curr Opin Chem Biol; 1998 Aug; 2(4):466-71. PubMed ID: 9736919
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases and their inhibitors in tumour growth and invasion.
Kähäri VM; Saarialho-Kere U
Ann Med; 1999 Feb; 31(1):34-45. PubMed ID: 10219712
[TBL] [Abstract][Full Text] [Related]
3. Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation.
Reynolds JJ
Oral Dis; 1996 Mar; 2(1):70-6. PubMed ID: 8957940
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.
Chapman KT; Kopka IE; Durette PL; Esser CK; Lanza TJ; Izquierdo-Martin M; Niedzwiecki L; Chang B; Harrison RK; Kuo DW
J Med Chem; 1993 Dec; 36(26):4293-301. PubMed ID: 8277511
[TBL] [Abstract][Full Text] [Related]
5. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.
Gallegos NC; Smales C; Savage FJ; Hembry RM; Boulos PB
Surg Oncol; 1995; 4(2):111-9. PubMed ID: 7551259
[TBL] [Abstract][Full Text] [Related]
6. [Matrix metalloproteinases and their biological functions].
Solov'eva NI
Bioorg Khim; 1998 Apr; 24(4):245-55. PubMed ID: 9612566
[TBL] [Abstract][Full Text] [Related]
7. Activation of tumor cell matrix metalloproteinase-2 by neutrophil proteinases requires expression of membrane-type 1 matrix metalloproteinase.
Schwartz JD; Shamamian P; Monea S; Whiting D; Marcus SG; Galloway AC; Mignatti P
Surgery; 1998 Aug; 124(2):232-8. PubMed ID: 9706143
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of fluorometric and zymographic methods as activity assays for stromelysins and gelatinases.
Quesada AR; Barbacid MM; Mira E; Fernández-Resa P; Márquez G; Aracil M
Clin Exp Metastasis; 1997 Jan; 15(1):26-32. PubMed ID: 9009103
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the interaction of TIMP-2 and MMPs: engineering the changes.
Hutton M; Butler GS; Wattam BA; Willenbrock F; Williamson RA; Murphy G
Ann N Y Acad Sci; 1999 Jun; 878():524-7. PubMed ID: 10415762
[No Abstract] [Full Text] [Related]
10. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.
Terada T; Okada Y; Nakanuma Y
Hepatology; 1996 Jun; 23(6):1341-4. PubMed ID: 8675149
[TBL] [Abstract][Full Text] [Related]
11. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.
Duivenvoorden WC; Hirte HW; Singh G
Invasion Metastasis; 1997; 17(6):312-22. PubMed ID: 9949290
[TBL] [Abstract][Full Text] [Related]
12. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3.
Cowell S; Knäuper V; Stewart ML; D'Ortho MP; Stanton H; Hembry RM; López-Otín C; Reynolds JJ; Murphy G
Biochem J; 1998 Apr; 331 ( Pt 2)(Pt 2):453-8. PubMed ID: 9531484
[TBL] [Abstract][Full Text] [Related]
13. Gelastatins, new inhibitors of matrix metalloproteinases from Westerdykella multispora F50733.
Lee HJ; Chung MC; Lee CH; Chun HK; Rhee JS; Kho YH
Ann N Y Acad Sci; 1999 Jun; 878():635-7. PubMed ID: 10415794
[No Abstract] [Full Text] [Related]
14. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
Wojtowicz-Praga S; Low J; Marshall J; Ness E; Dickson R; Barter J; Sale M; McCann P; Moore J; Cole A; Hawkins MJ
Invest New Drugs; 1996; 14(2):193-202. PubMed ID: 8913840
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer.
Zervos EE; Shafii AE; Rosemurgy AS
J Surg Res; 1999 Jan; 81(1):65-8. PubMed ID: 9889060
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size.
Romanic AM; White RF; Arleth AJ; Ohlstein EH; Barone FC
Stroke; 1998 May; 29(5):1020-30. PubMed ID: 9596253
[TBL] [Abstract][Full Text] [Related]
17. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type 1 matrix metalloproteinase.
Kinoshita T; Sato H; Takino T; Itoh M; Akizawa T; Seiki M
Cancer Res; 1996 Jun; 56(11):2535-8. PubMed ID: 8653693
[TBL] [Abstract][Full Text] [Related]
18. Stromal cell expression of components of matrix-degrading protease systems in human cancer.
Hewitt R; Danø K
Enzyme Protein; 1996; 49(1-3):163-73. PubMed ID: 8797004
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases during rat skin wound healing: evidence that membrane type-1 matrix metalloproteinase is a stromal activator of pro-gelatinase A.
Okada A; Tomasetto C; Lutz Y; Bellocq JP; Rio MC; Basset P
J Cell Biol; 1997 Apr; 137(1):67-77. PubMed ID: 9105037
[TBL] [Abstract][Full Text] [Related]
20. Defects in matrix metalloproteinase inhibitory stoichiometry and selective MMP induction in patients with nonischemic or ischemic dilated cardiomyopathy.
Coker ML; Zellner JL; Crumbley AJ; Spinale FG
Ann N Y Acad Sci; 1999 Jun; 878():559-62. PubMed ID: 10415772
[No Abstract] [Full Text] [Related]
[Next] [New Search]
